

## REMARKS

The specification is amended above to insert a reference to related cases.

The specification is amended to correct an obvious typographical error on page 235.

The correct recited chemical formula can be ascertained by the reference to the recited formula of Example 106a on page 234, lines 9-10.

Claim 21 is amended above to remove multiple dependancies.


New Claims 33-37 encompass the subject matter of the previously multi-dependent claim 21.

Claims 30-32 have been canceled without prejudice to filing future continuing applications.

No amendment of inventorship is necessitated by these amendments.

Early allowance of the claims is requested. Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, he is respectfully invited to call applicants' attorney.

Respectfully submitted,



Dated: May 12, 2005

(847)383-3372

(847)383-3391

Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43032  
Attorney for Applicants  
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA